| Not Yet Recruiting | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients Wi Berger Disease, Bergers Disease, IgA Nephropathy | Phase 3 | 2026-10-02 |
| Not Yet Recruiting | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Sup Hidradenitis Suppurativa (HS) | Phase 4 | 2026-08-21 |
| Not Yet Recruiting | PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan Metastatic Prostate Cancer | — | 2026-08-01 |
| Not Yet Recruiting | A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy | — | 2026-07-31 |
| Not Yet Recruiting | ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathec Spinal Muscular Atrophy | Phase 4 | 2026-07-01 |
| Not Yet Recruiting | A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Ag Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | Phase 2 | 2026-06-30 |
| Withdrawn | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive H Prostate Cancer | Phase 1 / Phase 2 | 2026-06-29 |
| Not Yet Recruiting | Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a S Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | 2026-06-15 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometaso Asthma | Phase 3 | 2026-05-29 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | Phase 3 | 2026-05-29 |
| Not Yet Recruiting | IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using IgA Nephropathy | — | 2026-05-29 |
| Not Yet Recruiting | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Mi Advanced Malignancies | Phase 1 | 2026-05-29 |
| Not Yet Recruiting | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment Advanced Malignancies and Hepatic Impairment | Phase 1 | 2026-05-18 |
| Not Yet Recruiting | A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patient Leukemia, Myeloid, Chronic-Phase | — | 2026-05-16 |
| Not Yet Recruiting | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Phase 1 | 2026-05-07 |
| Not Yet Recruiting | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | 2026-05-04 |
| Recruiting | Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | 2026-04-27 |
| Recruiting | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase 3 | 2026-04-15 |
| Recruiting | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and T Cardiovascular Disease and Lipoprotein(a) | Phase 3 | 2026-04-13 |
| Not Yet Recruiting | Remibrutinib Open Label Roll-over Post-trial Access Protocol Indication of the Parent Protocol | Phase 3 | 2026-04-10 |
| Not Yet Recruiting | A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis | — | 2026-04-07 |
| Not Yet Recruiting | A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive P Hypertension | — | 2026-04-01 |
| Not Yet Recruiting | A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coron Hidradenitis Suppurativa | — | 2026-03-31 |
| Not Yet Recruiting | Real World Adherence of PCSK9 Targeted Therapy Dyslipidemia, Hypercholesterolemia | — | 2026-03-30 |
| Recruiting | A Study to Assess the Effects of Zigakibart on IgA Nephropathy. Immunoglobulin A Nephropathy (IgAN) | Phase 2 | 2026-03-26 |
| Not Yet Recruiting | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Pos Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2026-03-26 |
| Recruiting | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Dis Huntington Disease | Phase 3 | 2026-03-24 |
| Recruiting | A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleu Secondary Malignancies of T-cell Origin | — | 2026-03-23 |
| Recruiting | Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in Chin HR+/HER2- Advanced or Metastatic Breast Cancer | — | 2026-03-20 |
| Recruiting | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction Heart Failure With Reduced Ejection Fraction | Phase 1 | 2026-03-18 |
| Recruiting | Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizop Schizophrenia | Phase 2 | 2026-03-16 |
| Completed | A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China Chronic Urticaria | — | 2026-03-10 |
| Recruiting | A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atr Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | 2026-03-09 |
| Recruiting | A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Non-segmental Vitiligo | Phase 2 | 2026-03-09 |
| Recruiting | Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China Chronic Myeloid Leukemia in Chronic Phase | — | 2026-02-12 |
| Recruiting | Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) Metastatic Prostate Cancer | — | 2026-02-04 |
| Recruiting | Remibrutinib in Real-world Clinical Practice - a US Sub-study Chronic Spontaneous Urticaria | — | 2026-02-02 |
| Recruiting | Remibrutinib in Real-world Clinical Practice Chronic Spontaneous Urticaria | — | 2026-02-02 |
| Not Yet Recruiting | Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study Kidney Diseases | — | 2026-02-01 |
| Active Not Recruiting | A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Frac Heart Failure With Reduced Ejection Fraction | — | 2026-01-28 |
| Recruiting | Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib Breast Cancer | — | 2026-01-23 |
| Active Not Recruiting | A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab Multiple Sclerosis | — | 2026-01-22 |
| Recruiting | A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients Chronic Spontaneous Urticaria | — | 2026-01-17 |
| Recruiting | A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer Metastatic Prostate Cancer (mCRPC) | Phase 1 | 2026-01-14 |
| Recruiting | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | 2026-01-13 |
| Recruiting | REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria (PNH) | — | 2026-01-13 |
| Not Yet Recruiting | CHART-C3G/CLNP023B12011 C3 Glomerulopathy, Complement-mediated Kidney Disease, Proteinuria | — | 2026-01-01 |
| Recruiting | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast C Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | 2025-12-29 |
| Recruiting | Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis | — | 2025-12-22 |
| Recruiting | Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormo Breast Cancer | — | 2025-12-22 |
| Recruiting | Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters. Breast Cancer | — | 2025-12-15 |
| Recruiting | Real-world Secukinumab Outcomes in Canadian HS Patients Hidradenitis Suppurativa | — | 2025-12-12 |
| Recruiting | Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy A Cryptosporidiosis | Phase 2 | 2025-12-08 |
| Recruiting | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination W PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | 2025-12-05 |
| Recruiting | A Study of DII235 in Adults With Elevated Lipoprotein(a) Lipoprotein Disorder | Phase 2 | 2025-12-02 |
| Not Yet Recruiting | Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA) | — | 2025-12-01 |
| Recruiting | Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice | — | 2025-11-28 |
| Recruiting | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients Wit Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | 2025-11-27 |
| Recruiting | Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patien Atherosclerotic Cardiovascular Disease | Phase 4 | 2025-11-26 |
| Recruiting | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer | Phase 1 | 2025-11-24 |
| Recruiting | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants W Chronic Kidney Disease | Phase 1 | 2025-11-20 |
| Not Yet Recruiting | A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Cl Chronic Myelogenous Leukemia - Chronic Phase | — | 2025-11-15 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | 2025-11-11 |
| Recruiting | Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Atopic Dermatitis | Phase 2 | 2025-11-10 |
| Recruiting | A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult P Still´s Disease | Phase 2 | 2025-11-03 |
| Recruiting | A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | Phase 2 | 2025-10-28 |
| Recruiting | Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | 2025-10-28 |
| Recruiting | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer | Phase 1 | 2025-10-16 |
| Recruiting | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 Progressive Metastatic Castrate Resistant Prostate Cancer | Phase 1 / Phase 2 | 2025-10-15 |
| Recruiting | EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | 2025-10-09 |
| Recruiting | Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acu Acute Coronary Syndrome | Phase 3 | 2025-10-03 |
| Recruiting | A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A Charcot-Marie-Tooth Disease, Type 1A | Phase 1 | 2025-09-30 |
| Recruiting | Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients Myocardial Infarction | — | 2025-09-30 |
| Recruiting | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secuk Juvenile Psoriatic Arthritis | Phase 1 | 2025-09-24 |
| Recruiting | Fabhalta Capsules Specified Drug-use Survey C3 Glomerulopathy | — | 2025-09-17 |
| Active Not Recruiting | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | 2025-09-11 |
| Recruiting | Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Gra Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease | Phase 4 | 2025-09-09 |
| Recruiting | RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Ear HR+/HER2- Early Breast Cancer | — | 2025-08-27 |
| Not Yet Recruiting | A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | 2025-08-20 |
| Recruiting | Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) Primary Hypercholesterolemia or Mixed Dyslipidemia | — | 2025-08-13 |
| Recruiting | A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2025-08-07 |
| Recruiting | Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostat Metastatic Castration Resistant Prostate Cancer | — | 2025-07-30 |
| Terminated | NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice Paroxysmal Nocturnal Hemoglobinuria | — | 2025-07-29 |
| Recruiting | Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases | Phase 3 | 2025-07-28 |
| Completed | A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impai Autoimmune and Chronic Inflammatory Diseases | Phase 1 | 2025-07-23 |
| Recruiting | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Mul Relapsing Multiple Sclerosis | Phase 3 | 2025-07-23 |
| Recruiting | A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Chronic Spontaneous Urticaria (CSU) | Phase 3 | 2025-07-11 |
| Recruiting | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Me Metastatic Hormone-sensitive Prostate Cancer | Phase 2 | 2025-07-07 |
| Active Not Recruiting | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Ca Prostatic Cancer, Castration-Resistant | Phase 2 | 2025-07-03 |
| Recruiting | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC Prostate Cancer | Phase 3 | 2025-07-01 |
| Recruiting | A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) | Phase 1 / Phase 2 | 2025-06-20 |
| Active Not Recruiting | Inclisiran Effectiveness in China: a Pragmatic Randomized Trial Coronary Heart Disease | Phase 4 | 2025-06-17 |
| Recruiting | Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hyperchole Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia | — | 2025-06-16 |
| Recruiting | An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 1 | 2025-06-12 |
| Recruiting | A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in C Paroxysmal Nocturnal Hemoglobinuria | — | 2025-06-10 |
| Completed | A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy Muscular Atrophy, Spinal | — | 2025-06-04 |
| Recruiting | DFT383 in Pediatric Participants With Nephropathic Cystinosis Nephropathic Cystinosis | Phase 1 / Phase 2 | 2025-06-02 |
| Recruiting | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | Phase 3 | 2025-05-30 |
| Recruiting | Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | 2025-05-22 |
| Recruiting | Pelacarsen Roll-over Extension Program Atherosclerotic Cardiovascular Disease | Phase 3 | 2025-05-19 |
| Recruiting | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Pa Lupus Nephritis | Phase 3 | 2025-05-19 |
| Recruiting | Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Atopic Dermatitis | Phase 2 | 2025-05-16 |
| Completed | Concept Elicitation and Patient Experience Mapping in SA-AKI Sepsis-associated Acute Kidney Injury | — | 2025-05-01 |
| Not Yet Recruiting | Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Act Juvenile Idiopathic Arthritis | — | 2025-04-30 |
| Recruiting | Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | 2025-04-30 |
| Recruiting | A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. Chagas Disease | Phase 2 | 2025-04-28 |
| Recruiting | Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis Generalized Myasthenia Gravis | Phase 1 / Phase 2 | 2025-04-22 |
| Recruiting | Post Marketing Study on Pluvicto in Korea Metastatic Castration-resistant Prostate Cancer | — | 2025-04-18 |
| Recruiting | Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia Atherosclerotic Cardiovascular Disease | — | 2025-04-15 |
| Recruiting | Home Reported Outcomes in C3G Study C3 Glomerulopathy | — | 2025-04-07 |
| Recruiting | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Adv Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | 2025-04-03 |
| Recruiting | Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. Ankylosing Spondylitis | — | 2025-04-02 |
| Active Not Recruiting | Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Hemoglobinuria, Paroxysmal | — | 2025-03-31 |
| Recruiting | Ilaris NIS in Korea Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF) | — | 2025-03-29 |
| Recruiting | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients Hypertension | Phase 2 | 2025-03-26 |
| Recruiting | RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC Chronic Myelogenous Leukemia in Chronic Phase | — | 2025-03-24 |
| Recruiting | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients Wi Hidradenitis Suppurativa | Phase 3 | 2025-03-20 |
| Withdrawn | Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to M Renal Impairment | Phase 1 | 2025-03-19 |
| Recruiting | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA ANCA Associated Vasculitis (AAV) | Phase 2 | 2025-03-13 |
| Active Not Recruiting | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Relapsing Multiple Sclerosis (RMS) | Phase 3 | 2025-03-13 |
| Recruiting | Long-term Follow up Local Registry Study of Kymriah in South Korea B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | — | 2025-03-12 |
| Active Not Recruiting | Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Init Hidradenitis Suppurativa | — | 2025-03-10 |
| Recruiting | Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinic Hidradenitis Suppurativa (HS) | — | 2025-03-10 |
| Withdrawn | Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Match Hepatic Impairment | Phase 1 | 2025-03-06 |
| Recruiting | A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (Ig Immunoglobulin A Nephropathy | — | 2025-03-04 |
| Recruiting | Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hyperch Familial Hypercholesterolemia - Homozygous | Phase 3 | 2025-02-28 |
| Recruiting | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive Prostate Cancer | Phase 2 / Phase 3 | 2025-02-27 |
| Recruiting | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Scle Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | 2025-02-24 |
| Recruiting | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With Ig Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase 2 | 2025-02-21 |
| Recruiting | A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Tr Breast Neoplasms | — | 2025-02-20 |
| Recruiting | Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant Chronic Myeloid Leukemia (CML) | Phase 2 | 2025-02-18 |
| Recruiting | LATAM LOWERS LDL-C Hypercholesterolaemia | Phase 4 | 2025-02-11 |
| Recruiting | A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients Generalized Myasthenia Gravis | Phase 3 | 2025-02-07 |
| Recruiting | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients Wi Hidradenitis Suppurativa | Phase 3 | 2025-01-31 |
| Recruiting | Modifying PEST for Psoriatic Arthritis Screening Plaque Psoriasis, Psoriatic Arthritis | N/A | 2025-01-23 |
| Completed | A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Ad Hypercholesterolemia, Mixed Dyslipidemia | — | 2025-01-23 |
| Withdrawn | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2024-12-20 |
| Recruiting | Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure) Pediatric Chronic Heart Failure | — | 2024-12-19 |
| Recruiting | Phase 2 Study of Rapcabtagene Autoleucel in Myositis Idiopathic Inflammatory Myopathies | Phase 2 | 2024-12-17 |
| Recruiting | Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Followi Progressive Multiple Sclerosis | Phase 1 / Phase 2 | 2024-12-12 |
| Completed | Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macula Diabetic Macular Edema | Phase 4 | 2024-12-11 |
| Recruiting | Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study Relapsing Multiple Sclerosis (RMS) | — | 2024-12-10 |
| Recruiting | Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemi Familial Hypercholesterolemia - Heterozygous | Phase 3 | 2024-12-09 |
| Completed | Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and i Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | 2024-11-28 |
| Recruiting | ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | 2024-11-27 |
| Active Not Recruiting | Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis Multiple Sclerosis | Phase 4 | 2024-11-25 |
| Withdrawn | Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sjogren Disease, Systemic Lupus Erythematosus | Phase 1 | 2024-11-25 |
| Completed | Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation Multiple Sclerosis | — | 2024-11-15 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 4 | 2024-11-12 |
| Recruiting | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Tr Metastatic Castration-Resistant Prostate Cancer | Phase 1 | 2024-11-11 |
| Completed | A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Ther Muscular Atrophy, Spinal | — | 2024-11-06 |
| Recruiting | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis Scleroderma, Diffuse | Phase 2 | 2024-10-29 |
| Recruiting | A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Seru Multiple Sclerosis | — | 2024-10-28 |
| Recruiting | A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent Sickle Cell Disease | Phase 3 | 2024-10-24 |
| Recruiting | A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Par Healthy Volunteers, Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | 2024-10-24 |
| Active Not Recruiting | A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | 2024-10-17 |
| Recruiting | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer | Phase 1 | 2024-10-15 |
| Active Not Recruiting | A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine The HR+HER2- Advanced Breast Cancer | — | 2024-10-11 |
| Recruiting | A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis Diffuse Cutaneous Systemic Sclerosis | Phase 2 | 2024-10-09 |
| Recruiting | An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). Systemic Lupus Erythematosus, SLE | Phase 1 | 2024-10-08 |
| Completed | A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treate Breast Cancer | — | 2024-10-08 |
| Recruiting | Specified Drug-use Surveillance of Fabhalta Capsules Paroxysmal Nocturnal Hemoglobinuria | — | 2024-09-18 |
| Terminated | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Ovarian Cancer, Lung Cancer | Phase 1 | 2024-09-08 |
| Recruiting | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 | 2024-09-04 |
| Completed | A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Prostate Cancer | — | 2024-09-04 |
| Recruiting | Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer | — | 2024-09-04 |
| Recruiting | A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease Sickle Cell Disease | Phase 1 / Phase 2 | 2024-08-15 |
| Recruiting | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patien Breast Cancer | Phase 1 / Phase 2 | 2024-08-14 |
| Recruiting | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Hematologic Malignancy, Solid Tumor, Advanced Malignancies | Phase 3 | 2024-08-13 |
| Active Not Recruiting | Iptacopan in Patients With ANCA Associated Vasculitis Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | 2024-08-05 |
| Recruiting | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Parti Generalized Myasthenia Gravis | Phase 3 | 2024-07-31 |
| Active Not Recruiting | ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients Multiple Sclerosis, Relapsing-Remitting | — | 2024-07-30 |
| Active Not Recruiting | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer | Phase 1 | 2024-07-29 |
| Active Not Recruiting | Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients Wit Hidradenitis Suppurativa | — | 2024-07-26 |
| Recruiting | Revolade Tablets Specified Drug-use Survey Aplastic Anemia | — | 2024-07-17 |
| Recruiting | Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction Plaque, Atherosclerotic | Phase 4 | 2024-07-09 |
| Recruiting | Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Steroid-refractory Acute Graft Versus Host Disease | Phase 4 | 2024-07-04 |
| Active Not Recruiting | Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Betw Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 2 | 2024-07-02 |
| Recruiting | Kesimpta Pregnancy and Infant Safety Study Using Real World Data Multiple Sclerosis | — | 2024-06-30 |
| Active Not Recruiting | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) Polymyalgia Rheumatica | Phase 3 | 2024-06-28 |
| Completed | A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With At Hypercholesterolemia | Phase 4 | 2024-06-21 |
| Active Not Recruiting | Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation Hidradenitis Suppurativa | — | 2024-06-17 |
| Active Not Recruiting | A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Ge Chronic Spontaneous Urticaria | — | 2024-06-11 |
| Recruiting | Home Reported Outcomes in PNH Paroxysmal Nocturnal Hemoglobinuria | — | 2024-06-11 |
| Terminated | Migraine Survey in Gulf Region Migraine | — | 2024-06-05 |
| Completed | A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer Metastatic HR+/HER2- Breast Cancer | — | 2024-05-30 |
| Recruiting | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythema Systemic Lupus Erythematosus | Phase 3 | 2024-05-21 |
| Active Not Recruiting | Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma Newly Diagnosed and Recurrent Glioblastoma | Phase 1 | 2024-05-15 |
| Recruiting | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Atypical Hemolytic Uremic Syndrome | Phase 3 | 2024-05-08 |
| Completed | A Study of Real-world Outcomes Among Patients Treated With Ribociclib Metastatic Breast Cancer | — | 2024-04-24 |
| Completed | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevat Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | Phase 3 | 2024-04-24 |
| Completed | A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patient Secondary Progressive Multiple Sclerosis | — | 2024-04-16 |
| Active Not Recruiting | Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Sickle Cell Disease | Phase 1 | 2024-04-16 |
| Completed | A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, Leukemia, Chronic Myeloid | — | 2024-04-08 |
| Completed | Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ69 Hypertension | Phase 3 | 2024-04-08 |
| Recruiting | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired an Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | 2024-04-04 |
| Completed | Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal Breast Cancer | — | 2024-03-29 |
| Completed | Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the Cardiovascular Disease | — | 2024-03-29 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GC Giant Cell Arteritis, Polymyalgia Rheumatica | Phase 1 | 2024-03-27 |
| Completed | A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Hea Neuroendocrine Neoplasms | Phase 3 | 2024-03-21 |
| Recruiting | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. Oligometastatic Prostate Cancer (OMPC) | Phase 3 | 2024-03-12 |
| Recruiting | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progressio Aortic Stenosis | Phase 2 | 2024-03-07 |
| Recruiting | A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer Breast Cancer | — | 2024-03-07 |
| Completed | Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria Uncomplicated Plasmodium Falciparum Malaria | Phase 3 | 2024-03-07 |
| Active Not Recruiting | Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- C Chronic Myeloid Leukemia | — | 2024-03-06 |
| Active Not Recruiting | Specified Drug-use Survey of Leqvio for s.c. Injection. Familial Hypercholesterolaemia, Hypercholesterolaemia | — | 2024-03-04 |
| Completed | A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure Heart Failure | — | 2024-03-03 |
| Recruiting | Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants Atypical Hemolytic Uremic Syndrome | Phase 3 | 2024-02-28 |
| Recruiting | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer Early Breast Cancer | Phase 3 | 2024-02-28 |
| Completed | Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment Leukemia, Chronic Myeloid | — | 2024-02-27 |
| Completed | A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Rela Relapsing Forms of Multiple Sclerosis | — | 2024-02-26 |
| Recruiting | A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever Dengue | Phase 2 | 2024-02-20 |
| Completed | A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in Chronic Spontaneous Urticaria | — | 2024-02-16 |
| Completed | A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Red Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP) | Phase 2 | 2024-02-15 |
| Recruiting | Special Drug Use-results Surveillance of Tafinlar/Mekinist BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor | — | 2024-02-09 |
| Completed | A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data Multiple Sclerosis, Relapsing-Remitting | — | 2024-02-09 |
| Recruiting | Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors | — | 2024-02-06 |
| Completed | Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Leukemia, Myeloid, Chronic-Phase | — | 2024-02-01 |
| Completed | Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization Post Operative Endophthalmitis | — | 2024-01-27 |
| Completed | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | 2024-01-23 |
| Recruiting | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plas Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | 2024-01-23 |
| Completed | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | 2024-01-23 |
| Active Not Recruiting | Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEA Acute Kidney Injury Due to Sepsis | Phase 2 | 2024-01-18 |
| Completed | A Study of the Epidemiology and Hospital Management of Patients With PROS in France PIK3CA-Related Overgrowth Spectrum | — | 2024-01-15 |
| Completed | Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Describ Chronic Iron Overload | — | 2024-01-12 |
| Active Not Recruiting | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive C Prostatic Neoplasm | Phase 2 | 2024-01-03 |
| Active Not Recruiting | Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis Moderate-to-severe Plaque Psoriasis | — | 2023-12-29 |
| Active Not Recruiting | A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or HR+HER2- Advanced Breast Cancer | — | 2023-12-28 |
| Active Not Recruiting | Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in Franc Multiple Sclerosis (MS) | — | 2023-12-21 |
| Terminated | A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure Heart Failure | Phase 2 | 2023-12-12 |
| Active Not Recruiting | A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With Chronic Inducible Urticaria | Phase 3 | 2023-12-07 |
| Completed | A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Heart Failure | Phase 3 | 2023-12-04 |
| Completed | WOE of Anti-CD20 Therapies Multiple Sclerosis | — | 2023-12-04 |
| Recruiting | Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study Relapsing Multiple Sclerosis | — | 2023-11-27 |
| Recruiting | Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Lymphatic Malformations | Phase 2 / Phase 3 | 2023-11-24 |
| Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Follicular Lymphoma | — | 2023-11-23 |
| Recruiting | A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgen Spinal Muscular Atrophies | — | 2023-11-22 |
| Active Not Recruiting | Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Chronic Spontaneous Urticaria | Phase 3 | 2023-11-15 |
| Recruiting | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanc Breast Cancer | Phase 1 | 2023-11-13 |
| Active Not Recruiting | Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT Prostate Cancer | Phase 1 / Phase 2 | 2023-11-07 |
| Completed | A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumum Multiple Sclerosis, Relapsing-Remitting | — | 2023-11-06 |
| Completed | In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Est Atherosclerotic Cardiovascular Disease | — | 2023-11-03 |
| Active Not Recruiting | A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long Sjogrens Syndrome | Phase 3 | 2023-10-27 |
| Completed | Effectiveness of Ofatumumab in Real-world Practice Multiple Sclerosis | — | 2023-10-24 |
| Completed | A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients Heart Failure | — | 2023-10-20 |
| Completed | A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in A Coronary Heart Disease | Phase 2 | 2023-10-16 |
| Terminated | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme | Phase 1 | 2023-10-06 |
| Recruiting | Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN IC-MPGN | Phase 3 | 2023-10-02 |
| Active Not Recruiting | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicul Follicular Lymphoma (FL) | Phase 3 | 2023-10-02 |
| Active Not Recruiting | An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) Hyperlipoproteinemia (a) | Phase 3 | 2023-09-29 |
| Withdrawn | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemothe Triple Negative Breast Cancer | Phase 2 | 2023-09-15 |
| Completed | An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhi Breast Cancer | — | 2023-09-08 |
| Completed | Special Drug Use Surveillance of Entresto Tablets (Hypertension) Hypertension | — | 2023-09-04 |
| Withdrawn | Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus | Phase 1 | 2023-09-01 |
| Active Not Recruiting | An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Huntington Disease | Phase 2 | 2023-08-25 |
| Active Not Recruiting | A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With a Primary Immune Thrombocytopenia (ITP) | Phase 2 | 2023-08-16 |
| Recruiting | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer Prostate Cancer | Phase 4 | 2023-08-14 |
| Active Not Recruiting | Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinum Hidradenitis Suppurativa | — | 2023-08-10 |
| Terminated | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy Rotator Cuff Tendinopathy | Phase 3 | 2023-08-10 |
| Terminated | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy Rotator Cuff Tendinopathy | Phase 3 | 2023-08-02 |
| Withdrawn | Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Dry Eye Disease | — | 2023-07-31 |
| Withdrawn | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemot Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 2023-07-28 |
| Terminated | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors Polycythemia Vera | Phase 4 | 2023-07-28 |
| Completed | Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | 2023-07-20 |
| Recruiting | Asciminib RMP Study Chronic Myeloid Leukemia | — | 2023-07-19 |
| Recruiting | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adoles Chronic Spontaneous Urticaria | Phase 3 | 2023-07-11 |
| Completed | Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevate Primary Hypercholesterolemia or Mixed Dyslipidemia | Phase 3 | 2023-07-11 |
| Active Not Recruiting | Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years Relapsing Multiple Sclerosis | — | 2023-07-10 |
| Active Not Recruiting | A Study of Zigakibart in Adults With IgA Nephropathy IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | 2023-07-06 |
| Active Not Recruiting | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase 1 | 2023-06-27 |
| Completed | A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617 Prostate Cancer | — | 2023-06-23 |
| Terminated | A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation | — | 2023-06-21 |
| Completed | A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Aplastic Anemia | — | 2023-06-21 |
| Completed | A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients Achilles Tendinopathy | Phase 2 | 2023-06-14 |
| Recruiting | A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea Non-Small-Cell Lung Carcinoma | — | 2023-06-12 |
| Completed | Epidemiology and Treatment of HR+/HER2- Breast Cancer in England Breast Cancer | — | 2023-06-08 |
| Completed | A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis Food Hypersensitivity, Anaphylaxis | — | 2023-06-01 |
| Completed | Safety and Efficacy of RHH646 for Knee Osteoarthritis Osteoarthritis, Knee | Phase 2 | 2023-05-31 |
| Completed | Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Th Chronic Myeloid Leukemia | — | 2023-05-23 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adul Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | 2023-05-16 |
| Withdrawn | Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure | — | 2023-05-15 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesoni Asthma | Phase 3 | 2023-05-11 |
| Active Not Recruiting | Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases Myeloid Diseases | Phase 1 | 2023-05-08 |
| Active Not Recruiting | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment N Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | 2023-05-05 |
| Active Not Recruiting | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Wh Renal Angiomyolipoma | Phase 4 | 2023-05-01 |
| Terminated | Long-term Extension Study of Ligelizumab in Food Allergy Food Allergy | Phase 3 | 2023-04-27 |
| Completed | Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 W Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2023-04-24 |
| Active Not Recruiting | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythem Systemic Lupus Erythematosus | Phase 3 | 2023-04-21 |
| Recruiting | A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea Graft-versus-Host Disease | — | 2023-04-07 |
| Completed | A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic S Chronic Spontaneous Urticaria | Phase 3 | 2023-04-05 |
| Terminated | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumor Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma | Phase 1 | 2023-04-04 |
| Completed | Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care Heart Failure | — | 2023-04-03 |
| Completed | A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Mi Familial Mediterranean Fever | — | 2023-03-30 |
| Active Not Recruiting | A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyl Non-radiographic Axial Spondyloarthritis | Phase 4 | 2023-03-28 |
| Terminated | Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants Pulmonary Arterial Hypertension | Phase 2 | 2023-03-27 |
| Completed | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Polymyalgia Rheumatica | Phase 3 | 2023-03-22 |
| Completed | Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving L Hypercholesterolemia | Phase 3 | 2023-03-15 |
| Completed | Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resista Treatment-Resistant Depression | Phase 2 | 2023-03-13 |
| Active Not Recruiting | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. Primary Prevention of Atherosclerotic Cardiovascular Disease | Phase 3 | 2023-03-09 |
| Completed | A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects Mild Hypertension | Phase 1 | 2023-03-08 |
| Completed | A Study to Evaluate the Impact of Long-term Digital Education vs Standard of Care on LDL-C Levels in Post Myoc Myocardial Infarction | — | 2023-03-08 |
| Terminated | A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Acute Kidney Injury Following Cardiac Surgery | Phase 2 | 2023-03-03 |
| Active Not Recruiting | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycyt Polycythemia Vera | — | 2023-03-02 |
| Active Not Recruiting | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With System Systemic Lupus Erythematosus | Phase 3 | 2023-03-02 |
| Completed | A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients Acute Lymphoblastic Leukemia | — | 2023-03-01 |
| Completed | A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertensi Hypertension | — | 2023-02-28 |
| Active Not Recruiting | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | 2023-02-28 |
| Terminated | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-a Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | 2023-02-23 |
| Recruiting | Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Pa Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | 2023-02-23 |
| Active Not Recruiting | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | 2023-02-13 |
| Active Not Recruiting | Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adole Heterozygous or Homozygous Familial Hypercholesterolemia | Phase 3 | 2023-02-10 |
| Completed | Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | 2023-02-06 |
| Active Not Recruiting | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia Primary Immune Thrombocytopenia (ITP) | Phase 3 | 2023-02-03 |
| Active Not Recruiting | A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thromb Primary Immune Thrombocytopenia | Phase 3 | 2023-02-02 |
| Withdrawn | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia | Phase 1 | 2023-01-24 |
| Completed | Patterns of Inclisiran Use in the Real World: An Analysis of US Databases Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia | — | 2023-01-20 |
| Completed | A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Parti Retinopathy of Prematurity | — | 2023-01-13 |
| Completed | Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps Chronic Rhinosinusitis With Nasal Polyps | — | 2023-01-12 |
| Completed | Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administere Spinal Muscular Atrophy | Phase 3 | 2023-01-12 |
| Completed | An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characteriz Major Depressive Disorder | Phase 1 | 2023-01-11 |
| Completed | The 'Wearing Off' Effect of DMT Multiple Sclerosis | — | 2023-01-10 |
| Recruiting | Kesimpta (Ofatumumab) Pregnancy Registry Multiple Sclerosis, Pregnancy | — | 2023-01-05 |
| Active Not Recruiting | A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anem Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 | 2022-12-30 |
| Terminated | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Neuroblastoma | Phase 1 | 2022-12-27 |
| Completed | A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib Breast Cancer | — | 2022-12-21 |
| Recruiting | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials Spinal Muscular Atrophy (SMA) | Phase 3 | 2022-12-19 |
| Active Not Recruiting | Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastat Breast Cancer | — | 2022-12-13 |
| Active Not Recruiting | An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urtic Chronic Spontaneous Urticaria | Phase 3 | 2022-12-09 |
| Completed | Characterizing the Use of Ofatumumab in a Real World Setting Relapsing Multiple Sclerosis | — | 2022-12-08 |
| Active Not Recruiting | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | Phase 2 | 2022-12-06 |
| Completed | Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepati Hepatic Impairment | Phase 1 | 2022-12-02 |
| Completed | Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy Tendinopathy | Phase 3 | 2022-12-02 |
| Completed | Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury Acute Kidney Injury Due to Sepsis | Phase 2 | 2022-11-22 |
| Active Not Recruiting | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Particip Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Phase 3 | 2022-11-21 |
| Completed | Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Data Psoriatic Arthritis, Psoriasis | — | 2022-11-17 |
| Active Not Recruiting | Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | 2022-11-11 |
| Terminated | To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF Idiopathic Pulmonary Fibrosis | Phase 2 | 2022-11-10 |
| Terminated | A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA Osteoarthritis, Knee | Phase 2 | 2022-11-09 |
| Completed | An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Resistant Hypertension | Phase 2 | 2022-11-08 |
| Completed | A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Hepatic Impairment | Phase 1 | 2022-10-31 |
| Completed | Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Multiple Sclerosis | — | 2022-10-28 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell | Phase 1 | 2022-10-26 |
| Active Not Recruiting | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutati KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2022-10-24 |
| Completed | A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Psoriasis | N/A | 2022-10-20 |
| Completed | Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts Allergy, Peanut | Phase 2 | 2022-10-12 |
| Terminated | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 1 | 2022-10-05 |
| Completed | Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping M Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation | — | 2022-10-03 |
| Active Not Recruiting | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | 2022-10-03 |
| Completed | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remi Giant Cell Arteritis | Phase 3 | 2022-09-29 |
| Completed | Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positiv BRAF-positive Metastatic Melanoma | — | 2022-09-28 |
| Completed | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United Stat Chronic Myeloid Leukemia | — | 2022-09-20 |
| Active Not Recruiting | Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD Primary Hypercholesterolemia, Mixed Dyslipidemia | — | 2022-09-12 |
| Completed | A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in Moderate to Severe Chronic Plaque Psoriasis | — | 2022-09-08 |
| Completed | A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age Neovascular Age-Related Macular Degeneration | — | 2022-09-06 |
| Completed | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. Non-Small Cell Lung Carcinoma | Phase 4 | 2022-09-03 |
| Completed | Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection Diabetic Macular Edema | — | 2022-09-02 |
| Recruiting | Asciminib Roll-over Study Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | 2022-08-30 |
| Recruiting | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Asthma | Phase 2 | 2022-08-29 |
| Terminated | Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus N Lupus Nephritis | Phase 3 | 2022-08-22 |
| Completed | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of We Hyperlipoproteinemia(a) | Phase 3 | 2022-08-19 |
| Withdrawn | Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Active Peripheral Spondyloarthritis (pSpA) | Phase 3 | 2022-08-16 |
| Completed | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. Diffuse Large B-cell Lymphoma | — | 2022-08-11 |
| Terminated | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC Non-small Cell Lung Cancer | Phase 2 | 2022-08-10 |
| Recruiting | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V Lupus Nephritis | Phase 2 | 2022-08-10 |
| Completed | Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breas Metastatic Breast Cancer | — | 2022-08-10 |
| Completed | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, H Advanced Breast Cancer | Phase 4 | 2022-08-09 |
| Active Not Recruiting | Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome Sjogren Syndrome | Phase 3 | 2022-08-04 |
| Active Not Recruiting | Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome Sjogren Syndrome | Phase 3 | 2022-07-28 |
| Completed | Secondary Use of PARALLEL-HF Data Chronic Heart Failure and Reduced Ejection Fraction (HFrEF) | — | 2022-07-27 |
| Completed | Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships Sjogren Syndrome | Phase 2 | 2022-07-27 |
| Completed | Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Relapsing Multiple Sclerosis | — | 2022-07-26 |
| Completed | Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China Relapsing Multiple Sclerosis | Phase 4 | 2022-07-22 |
| Recruiting | Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants W Lupus Nephritis | Phase 3 | 2022-07-14 |
| Active Not Recruiting | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide Extensive Stage Small Cell Lung Cancer | Phase 1 / Phase 2 | 2022-07-13 |
| Active Not Recruiting | Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Stati Coronary Artery Disease | Phase 3 | 2022-07-08 |
| Active Not Recruiting | Roll-over Study to Allow Continued Access to Ribociclib Metastatic Breast Cancer | Phase 4 | 2022-07-07 |
| Completed | A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan Myeloid Leukemia, Chronic | — | 2022-07-05 |
| Completed | Special Drug Use-results Surveillance of Scemblix Tablets Chronic Myeloid Leukemia | — | 2022-07-04 |
| Active Not Recruiting | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Metastatic Uveal Melanoma | Phase 1 / Phase 2 | 2022-07-04 |
| Terminated | Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension | Phase 2 | 2022-06-30 |
| Recruiting | A Post Marketing Surveillance on Piqray in Korea Breast Cancer | — | 2022-06-29 |
| Completed | Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity Retinopathy of Prematurity | — | 2022-06-22 |
| Completed | Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy Active Secondary Progressive Multiple Sclerosis | — | 2022-06-17 |
| Active Not Recruiting | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mut Non-Small Cell Lung Cancer | Phase 3 | 2022-06-15 |
| Completed | Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic BRAF Positive Metastatic Melanoma | — | 2022-06-08 |
| Completed | Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real- Dry Eye Disease | — | 2022-06-02 |
| Completed | Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Neovascular (Wet) Age-related Macular Degeneration | — | 2022-05-31 |
| Completed | A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab Multiple Sclerosis | — | 2022-05-20 |
| Terminated | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Acute Myeloid Leukemia | Phase 1 | 2022-05-17 |
| Completed | Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | Phase 1 | 2022-05-17 |
| Completed | Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spect PIK3CA-related Overgrowth Spectrum | — | 2022-05-16 |
| Completed | Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study Multiple Sclerosis | — | 2022-05-12 |
| Recruiting | A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis | — | 2022-05-10 |
| Completed | A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametin BRAF V600 Mutation Positive Melanoma | — | 2022-05-10 |
| Completed | A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancre Somatostatin Receptor-positive GEP-NET | — | 2022-05-10 |
| Active Not Recruiting | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Ca Glioblastoma | Phase 1 | 2022-05-10 |
| Recruiting | A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® Asthma | — | 2022-05-09 |
| Recruiting | A 24-week rPMS Study in Real-world Setting for Enerzair Asthma | — | 2022-05-09 |
| Completed | Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Spinal Muscular Atrophy | — | 2022-05-05 |
| Completed | Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Aplastic Anemia (AA) | — | 2022-05-05 |
| Completed | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Small Cell Lung Carcinoma | Phase 1 | 2022-05-03 |
| Completed | First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2022-04-29 |
| Completed | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz Malaria | Phase 1 | 2022-04-28 |
| Active Not Recruiting | The Belgian REAL (BE.REAL) Registry Atherosclerotic Cardiovascular Disease | — | 2022-04-15 |
| Terminated | Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulatio Healthy Volunteers | Phase 1 | 2022-04-13 |
| Terminated | Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting Neovascular Age-related Macular Degeneration | — | 2022-04-13 |
| Completed | Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoi Hypercholesterolemia | Phase 4 | 2022-04-08 |
| Completed | Study of Efficacy and Safety of ABO809 in Healthy Participants Cryptosporidium Infection, Cryptosporidiosis | Phase 1 | 2022-04-07 |
| Completed | A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib Myelofibrosis | — | 2022-04-07 |
| Terminated | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER Breast Cancer | Phase 2 | 2022-04-06 |
| Completed | 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treat Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis | — | 2022-03-25 |
| Terminated | STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS Myelodysplastic Syndrome (MDS) | Phase 2 | 2022-03-17 |
| Completed | A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanc HR+/HER2- Advanced or Metastatic Breast Cancer | — | 2022-03-16 |
| Terminated | Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE) Lupus Erythematosus, Systemic | Phase 1 | 2022-03-15 |
| Completed | Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subs Chronic Heart Failure | — | 2022-03-11 |
| Completed | Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients Wi Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | 2022-03-09 |
| Completed | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Met Malaria | Phase 1 | 2022-03-09 |
| Terminated | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Advanced Breast Cancer | Phase 2 | 2022-03-08 |
| Completed | To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmo Severe Malaria | Phase 2 | 2022-03-07 |
| Terminated | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma Multiple Myeloma | Phase 2 | 2022-03-03 |
| Active Not Recruiting | A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevati Relapsing-Remitting Multiple Sclerosis | Phase 4 | 2022-03-02 |
| Completed | Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Cou Breast Cancer | — | 2022-02-28 |
| Active Not Recruiting | A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration Age-Related Macular Degeneration | Phase 2 | 2022-02-17 |
| Completed | Adherence and Persistence to Inclisiran Among Early Users in Germany High Levels of Low-density Lipoprotein Cholesterol | — | 2022-02-16 |
| Withdrawn | An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Asthma | — | 2022-02-15 |
| Completed | Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, Ps Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis | — | 2022-02-14 |
| Completed | Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Olde Fascioliasis | Phase 4 | 2022-02-11 |
| Terminated | Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or With Obesity | Phase 2 | 2022-02-10 |
| Completed | Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpe Healthy Volunteers | Phase 1 | 2022-02-03 |
| Completed | Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy Type 2 Spinal Muscular Atrophy | Phase 3 | 2022-02-01 |
| Completed | A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowe Hypercholesterolemia | — | 2022-01-31 |
| Withdrawn | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgk Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | 2022-01-31 |
| Active Not Recruiting | Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | 2022-01-27 |
| Completed | Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Heal Relapse Remitting Multiple Sclerosis | Phase 4 | 2022-01-25 |
| Active Not Recruiting | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan Prostate Cancer | Phase 2 | 2022-01-25 |
| Terminated | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodg Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | Phase 1 | 2022-01-24 |
| Active Not Recruiting | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to C Atypical Hemolytic Uremic Syndrome | Phase 3 | 2022-01-17 |
| Completed | A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled Chronic Spontaneous Urticaria | Phase 3 | 2022-01-15 |
| Completed | Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescript Neovascular Age-related Macular Degeneration | — | 2022-01-07 |
| Completed | Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab Multiple Sclerosis | — | 2022-01-05 |
| Completed | A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular A Neurovascular Age-related Macular Degeneration | — | 2022-01-05 |
| Completed | Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T3 Chronic Myeloid Leukemia With T315I Mutation | — | 2021-12-31 |
| Recruiting | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia Myeloid Leukemia, Philadelphia Positive | Phase 1 / Phase 2 | 2021-12-27 |
| Terminated | Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disord Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD) | Phase 2 | 2021-12-21 |
| Completed | LUTATHERA Injection General Use Result Survey Somatostatin Receptor-positive Neuroendocrine Tumor | — | 2021-12-17 |
| Active Not Recruiting | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), Breast Cancer | Phase 3 | 2021-12-17 |
| Active Not Recruiting | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosi Relapsing Multiple Sclerosis | Phase 3 | 2021-12-16 |
| Recruiting | Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent Multiple Sclerosis | — | 2021-12-15 |
| Active Not Recruiting | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosi Relapsing Multiple Sclerosis | Phase 3 | 2021-12-13 |
| Completed | Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patie Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 Mutations | — | 2021-12-10 |
| Completed | Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment Hepatic Impairment | Phase 1 | 2021-12-10 |
| Completed | Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholest Primary Hypercholesterolemia, Mixed Dyslipidemia | — | 2021-12-09 |
| Terminated | A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Early Manifest Huntington Disease | Phase 2 | 2021-12-08 |
| Terminated | Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy Allergy, Peanut | Phase 3 | 2021-12-07 |
| Completed | Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previous Leukemia, Chronic Myelogenous | Phase 2 | 2021-12-06 |
| Completed | Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials Multiple Sclerosis | — | 2021-12-02 |
| Completed | Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma Melanoma | — | 2021-12-01 |
| Completed | Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Br Neovascular Age-related Macular Degeneration | — | 2021-12-01 |
| Completed | A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controll Chronic Spontaneous Urticaria | Phase 3 | 2021-12-01 |
| Terminated | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Rena Carcinoma, Renal Cell | Phase 1 | 2021-11-30 |
| Withdrawn | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL B-cell Acute Lymphoblastic Leukemia | Phase 2 | 2021-11-30 |
| Terminated | A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (S Sjogren Syndrome, Mixed Connective Tissue Disease | Phase 2 | 2021-11-30 |
| Completed | A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controll Chronic Spontaneous Urticaria | Phase 3 | 2021-11-30 |
| Terminated | A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | 2021-11-29 |
| Completed | Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients de Novo Heart Failure | — | 2021-11-29 |
| Completed | A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indi Multiple Sclerosis | — | 2021-11-24 |
| Active Not Recruiting | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Dise Atherosclerotic Cardiovascular Disease | Phase 3 | 2021-11-23 |
| Completed | Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compa Hepatic Impairment | Phase 1 | 2021-11-23 |
| Terminated | Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice Neovascular Age-related Macular Degeneration | — | 2021-11-19 |
| Terminated | Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity | — | 2021-11-19 |
| Completed | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole Malaria | Phase 1 | 2021-11-18 |
| Terminated | Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Rem Chronic Inducible Urticaria | Phase 3 | 2021-11-16 |
| Terminated | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment Metastatic Colorectal Cancer | Phase 2 | 2021-11-15 |
| Active Not Recruiting | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Differentiated Thyroid Cancer (DTC) | Phase 3 | 2021-11-15 |
| Completed | Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe He Hepatic Impairment | Phase 1 | 2021-11-10 |
| Terminated | Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Cou Sickle Cell Disease | — | 2021-11-04 |
| Completed | Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) Muscular Atrophy, Spinal | Phase 4 | 2021-11-04 |
| Terminated | Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impai Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | 2021-10-28 |
| Completed | Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world Breast Cancer | — | 2021-10-27 |
| Active Not Recruiting | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors Mesothelioma | Phase 1 | 2021-10-21 |
| Terminated | Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib an Metastatic Melanoma | — | 2021-10-16 |
| Completed | Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) Malignant Melanoma | — | 2021-10-15 |
| Completed | Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Tr Neovascular Age-related Macular Degeneration | Phase 4 | 2021-10-15 |
| Terminated | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma | EARLY_Phase 1 | 2021-10-14 |
| Completed | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP Chronic Myelogenous Leukemia | Phase 3 | 2021-10-13 |
| Completed | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Giant Cell Arteritis (GCA) | Phase 3 | 2021-10-06 |
| Active Not Recruiting | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | 2021-10-06 |
| Active Not Recruiting | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Scl Multiple Sclerosis (MS) | Phase 3 | 2021-10-05 |
| Completed | Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpo Melanoma | — | 2021-10-02 |
| Completed | Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Metastatic Non-Small Cell Lung Cancer | — | 2021-10-01 |
| Completed | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line M Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | 2021-09-30 |
| Completed | Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarct Acute Myocardial Infarction | — | 2021-09-30 |
| Completed | Study of Diagnostic Performance of [18F]CTT1057 in BCR Prostatic Neoplasms, Prostate Cancer, Recurrence | Phase 3 | 2021-09-30 |
| Completed | A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinu Psoriasis | — | 2021-09-26 |
| Completed | Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD Pulmonary Disease, Chronic Obstructive | Phase 2 | 2021-09-24 |
| Terminated | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non- Carcinoma, Non-Small-Cell Lung | Phase 3 | 2021-09-22 |
| Recruiting | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/L Primary IgA Nephropathy | Phase 3 | 2021-09-20 |
| Completed | Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Synd Familial Cold Autoinflammatory Syndrome | Phase 2 | 2021-09-20 |
| Completed | Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis Symptomatic Knee Osteoarthritis | Phase 2 | 2021-09-20 |
| Terminated | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Diseas Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-09-14 |